205 related articles for article (PubMed ID: 33719954)
41. The farnesyltransferase inhibitor manumycin A is a novel trypanocide with a complex mode of action including major effects on mitochondria.
Ali BR; Pal A; Croft SL; Taylor RJ; Field MC
Mol Biochem Parasitol; 1999 Oct; 104(1):67-80. PubMed ID: 10589982
[TBL] [Abstract][Full Text] [Related]
42. Peptide specificity of protein prenyltransferases is determined mainly by reactivity rather than binding affinity.
Hartman HL; Hicks KA; Fierke CA
Biochemistry; 2005 Nov; 44(46):15314-24. PubMed ID: 16285735
[TBL] [Abstract][Full Text] [Related]
43. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.
Rowinsky EK; Windle JJ; Von Hoff DD
J Clin Oncol; 1999 Nov; 17(11):3631-52. PubMed ID: 10550163
[TBL] [Abstract][Full Text] [Related]
44. Proteomic identification of heat shock protein 70 as a candidate target for enhancing apoptosis induced by farnesyl transferase inhibitor.
Hu W; Wu W; Verschraegen CF; Chen L; Mao L; Yeung SC; Kudelka AP; Freedman RS; Kavanagh JJ
Proteomics; 2003 Oct; 3(10):1904-11. PubMed ID: 14625852
[TBL] [Abstract][Full Text] [Related]
45. [Anti tumor activity of farnesyl transferase inhibitor].
Yoshimatsu K; Nagasu T
Gan To Kagaku Ryoho; 1997 Jan; 24(2):145-55. PubMed ID: 9030225
[TBL] [Abstract][Full Text] [Related]
46. Suppression of human pancreatic cancer growth in BALB/c nude mice by manumycin, a farnesyl:protein transferase inhibitor.
Ito T; Kawata S; Tamura S; Igura T; Nagase T; Miyagawa JI; Yamazaki E; Ishiguro H; Matasuzawa Y
Jpn J Cancer Res; 1996 Feb; 87(2):113-6. PubMed ID: 8609057
[TBL] [Abstract][Full Text] [Related]
47. Farnesyltransferase inhibitors and anti-Ras therapy.
Gibbs JB; Kohl NE; Koblan KS; Omer CA; Sepp-Lorenzino L; Rosen N; Anthony NJ; Conner MW; deSolms SJ; Williams TM; Graham SL; Hartman GD; Oliff A
Breast Cancer Res Treat; 1996; 38(1):75-83. PubMed ID: 8825125
[TBL] [Abstract][Full Text] [Related]
48. Blockade of the Ras pathway by manumycin, a farnesyltransferase inhibitor, overcomes the resistance of myeloma plasma cells to Fas-induced apoptosis.
Frassanito MA; Mastromauro L; Cusmai A; Dammacco F
Clin Exp Med; 2005 Mar; 4(4):174-82. PubMed ID: 15750764
[TBL] [Abstract][Full Text] [Related]
49. Geranylgeranyltransferase I as a target for anti-cancer drugs.
Philips MR; Cox AD
J Clin Invest; 2007 May; 117(5):1223-5. PubMed ID: 17476354
[TBL] [Abstract][Full Text] [Related]
50. [Growth inhibition of human pancreatic cancer by farnesyl transferase inhibitor].
Kainuma O; Asano T; Hasegawa M; Isono K
Gan To Kagaku Ryoho; 1996 Oct; 23(12):1657-9. PubMed ID: 8886038
[TBL] [Abstract][Full Text] [Related]
51. Inhibitors of protein farnesyltransferase as novel anticancer agents.
Ohkanda J; Knowles DB; Blaskovich MA; Sebti SM; Hamilton AD
Curr Top Med Chem; 2002 Mar; 2(3):303-23. PubMed ID: 11944822
[TBL] [Abstract][Full Text] [Related]
52. J-104,871, a novel farnesyltransferase inhibitor, blocks Ras farnesylation in vivo in a farnesyl pyrophosphate-competitive manner.
Yonemoto M; Satoh T; Arakawa H; Suzuki-Takahashi I; Monden Y; Kodera T; Tanaka K; Aoyama T; Iwasawa Y; Kamei T; Nishimura S; Tomimoto K
Mol Pharmacol; 1998 Jul; 54(1):1-7. PubMed ID: 9658183
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of human tumor cell growth in vitro and in vivo by a specific inhibitor of human farnesyltransferase: BIM-46068.
Prevost GP; Pradines A; Viossat I; Brezak MC; Miquel K; Lonchampt MO; Kasprzyk P; Favre G; Pignol B; Le Breton C; Dong J; Morgan B
Int J Cancer; 1999 Oct; 83(2):283-7. PubMed ID: 10471540
[TBL] [Abstract][Full Text] [Related]
54. Farnesyltransferase inhibitors reduce Ras activation and ameliorate acetaminophen-induced liver injury in mice.
Saha B; Nandi D
Hepatology; 2009 Nov; 50(5):1547-57. PubMed ID: 19739265
[TBL] [Abstract][Full Text] [Related]
55. Sequence dependence of protein isoprenylation.
Moores SL; Schaber MD; Mosser SD; Rands E; O'Hara MB; Garsky VM; Marshall MS; Pompliano DL; Gibbs JB
J Biol Chem; 1991 Aug; 266(22):14603-10. PubMed ID: 1860864
[TBL] [Abstract][Full Text] [Related]
56. Chemopreventive efficacy of promising farnesyltransferase inhibitors.
Lantry LE; Zhang Z; Crist KA; Wang Y; Hara M; Zeeck A; Lubet RA; You M
Exp Lung Res; 2000 Dec; 26(8):773-90. PubMed ID: 11195470
[TBL] [Abstract][Full Text] [Related]
57. Farnesyltransferase inhibitor manumycin targets IL1β-Ras-HIF-1α axis in tumor cells of diverse origin.
Sharma V; Shaheen SS; Dixit D; Sen E
Inflammation; 2012 Apr; 35(2):516-9. PubMed ID: 21556735
[TBL] [Abstract][Full Text] [Related]
58. Conversion of protein farnesyltransferase to a geranylgeranyltransferase.
Terry KL; Casey PJ; Beese LS
Biochemistry; 2006 Aug; 45(32):9746-55. PubMed ID: 16893176
[TBL] [Abstract][Full Text] [Related]
59. Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer.
Liu M; Sjogren AK; Karlsson C; Ibrahim MX; Andersson KM; Olofsson FJ; Wahlstrom AM; Dalin M; Yu H; Chen Z; Yang SH; Young SG; Bergo MO
Proc Natl Acad Sci U S A; 2010 Apr; 107(14):6471-6. PubMed ID: 20308544
[TBL] [Abstract][Full Text] [Related]
60. Farnesyltransferase inhibitor, manumycin a, prevents atherosclerosis development and reduces oxidative stress in apolipoprotein E-deficient mice.
Sugita M; Sugita H; Kaneki M
Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1390-5. PubMed ID: 17363690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
